The landmark approval of the first pill for postpartum depression offers an important new treatment for the 1 in 7 new mothers who experience the disorder.
Suicide is a leading cause of maternal mortality in the U.S.. And yet on its own, the new drug — promising as it is — isn’t enough. Consider that as many as half of women with postpartum depression go undiagnosed.
Nonetheless, the new pill is a remarkable breakthrough and one of several encouraging recent developments in women’s health — perhaps a sign that pharmaceutical companies are finally listening to the female half of the population.